Wells Fargo initiated coverage of Revvity with an Equal Weight rating and $95 price target. The firm sees opportunity for Revvity to accelerate growth across its Life Science & Diagnostics markets, but remains cautious near-term due to potential volatility around post-spin operations and pharma/biotech headwinds.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on RVTY: